Sharechat Logo

Ebos buys biomedical stake

By Phil Boeyen, ShareChat Business News Editor

Tuesday 4th December 2001

Text too small?
Medical distributor Ebos Group (NZSE: EBO) has taken a controlling interest in biomedical products manufacturer Biomed.

Ebos describes Biomed as a profitable niche business with annualised sales in the $5-6 million range and valuable brands registered in New Zealand and Australia. It also has long term licensing contracts for B.Braun pharmaceuticals in New Zealand.

"The Biomed business consists of clinical nutritionals - using B. Braun ingredients, pain management products, plasma volume expanders, medicine solutions mixing and packing and controlled drug preparation," says Ebos MD Mark Walker.

"Markets are public and private hospitals in New Zealand with a developing business in Australia and USA."

Ebos says its controlling interest in the business comes via its 74%-owned subsidiary, Health Support, which has agreed to purchase 51% of Biomed from the Crown. B. Braun Medical USA holds the other 49% of the joint venture.

"The sale has been transacted for cash with Biomed Investments, which is jointly owned by Auckland Healthcare and Waitemata Health," Ebos says.

Mr Walker says the move completes the first of the transactions that the company advised at its annual meeting in October.

"It is consistent with our growth strategy of acquiring interests in businesses that already represent excellent brands and also have the potential to develop and manufacture proprietary brands."

The sale price has not been disclosed but Ebos says the transaction will not require shareholder consent.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos shareholders approve $1.1 billion purchase of Symbion
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos lifts profit by 19%, targets growth in animal health
Ebos funding line smaller than previously flagged at $135 mln
Ebos Group
Ebos backs off British purchase, evaluates "significant" Australasian asset
Ebos reports higher profit, looks for acquisitions